Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Sema4 Holdings — J.P. Morgan Healthcare Conference 2022
22 slides from Genedx's conference presentation, Jan 10, 2022
Slide 1: Investor Presentation J.P. Morgan Healthcare Conference January 2022
Investor Presentation J.P. Morgan Healthcare Conference January 2022 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, co
Slide 3: A Patient-Centered Health Intelligence Company Leveraging Genomics and AI
A Patient-Centered Health Intelligence Company Leveraging Genomics and AI
Slide 4: Corporate Snapshot
Corporate Snapshot 1 Headcount as of December 31, 2021 2 Sema4's guidance is subject to certain assumptions, risks and uncertainties. See Disclaimer on slide 2. 3 Annualized Run Rate as of September 30, 2021 World-class team 1,200+ employees 160+ MDs/PhD’s1 2021 guidance $204-206M total revenue2 Mas
Slide 5: The Problem
The Problem Rapid advances in Genomics & AI... ...but limited impact on patients 5
Slide 6: Our Solution: A Holistic Approach to Patient Care
Cutting-edge science and methodologies Flexible, in-depth genomic solutions Contracted with all major national payors Predictive risk modeling Seamless workflow integration Dedicated patient engagement and support Affordable payment plans, self- pay pricing, and other financial assistance options av
Slide 7: Centrellis, our Flywheel for Patient Data and Insights
Clinical Trials Clinical Decision Support Population Health Models Patients & Provider Portals Real-World Evidence Drug Discovery Models …Combined with Centrellis, our Flywheel for Patient Data and Insights Third Parties EMR, Imaging, Molecular, Claims Health Systems EMR, Imaging, Molecular, Claims
Slide 8: Deep Partnership with Health Systems
Deep Partnership with Health Systems (Beginning with learning-based partners) 8 Conventional Genomics Model narrow menu sold direct to physicians no (or limited) data integration no or limited patient engagement Enabling Precision Medicine as the Standard of Care
Slide 9: Evolution Towards a Platform of Algorithms
Richness of Data Set & Relationships Increased Value to Patients, Providers, Pharma GENOMIC TESTING SOLUTIONS REVENUE SECONDARY INSIGHTS MONETIZE INFORMATION PLATFORM TO QUERY FOR INSIGHTS Information-rich genomic testing platform Novel disease models that inform clinical care and trials reducing co
Slide 10: The Value of Data: Must be Longitudinal and Prescriptive
The Value of Data: Must be Longitudinal and Prescriptive 10 DISEASE AREAS PATIENT IMPACT EPISODIC Point-in-time LONGITUDINAL Collected over time DESCRIPTIVE Explore data DIAGNOSTIC Understand data PREDICTIVE Use data PRESCRIPTIVE Provide value from data Oncology Reproductive Health Autoimmune Rare &
Slide 11: NorthShore: The First Six Months
NorthShore: The First Six Months
Slide 12: Enabling Biopharma Partners and Customers
Drive increased probability of success and terminate bad molecules sooner Reduce trial duration, minimize dose finding / escalation, better patient selectivity Maximize trial opportunity, reduce time to market, and optimize market access LEAD IDENTIFICATION EARLY CLINICAL PROTOCOL OPTIMIZATION Precl
Slide 13: Health System Partnerships Helping Accelerate Biopharma Partnerships
Centrellis® Health System Dominant Partnership Pharma Dominant Partnership HS-Pharm Synergistic Partnership Health System Partnerships Helping Accelerate Biopharma Partnerships Drug Discovery Collaboration Precision Medicine Drug Screening Collaboration Clinical Trial Match and Recruitment into Tria
Slide 14: 4Q Update: Strong Close to 2021
4Q Update: Strong Close to 20211 14 Will exceed 80,000 tests excluding COVID-19 Guidance was 73,000 - 79,0002 Expects total revenues in the range of $50-52 million Guidance was $46.6 - 49.6 million2 ~$400 million in Cash & Cash Equivalents as of 12/31/21 1 Our estimates of our fourth quarter 2021 re
Slide 15: Operational Improvements: Key Highlights and Future Focus
Operational Improvements: Key Highlights and Future Focus 15 Lab Operations Commercial Reach Pharma & Data Key Actions ▪ Hired seasoned SVP Lab Operations ▪ Key investments in Lab Automation Key Actions ▪ Increased salesforce headcount by 84% in 2021 Key Actions ▪ Hired Chief Data & Chief Science Of
Slide 16: Capital Allocation
Capital Allocation 16 Significant Capital Resources to Drive Long Term Strategy $400M Cash & Cash Equivalents $125M Revolver, undrawn1 Acquisition Criteria Include Enhance Our Reach into Health Systems Enhance Our Data Capabilities Commercial Revenue 1 Our estimates of our fourth quarter 2021 cash a
Slide 17: Thank you
Thank you
Slide 18: Appendix
Appendix
Slide 19: Historical COVID Revenue Mix
1Q20 2Q20 3Q20 FY20 1Q21 2Q21 3Q21 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% COVID 0% 6% 14% 18% 25% 8% 10% Other 1% 1% 2% 2% 2% 4% 4% 1 Certain periods do not add to 100% due to rounding Historical COVID Revenue Mix % of Total Revenue1 19
Slide 20: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD Millions 20
Slide 21: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD Millions 21
Slide 22: SMFR semsa4
SMFR semsa4 Nasdaq Listed sema4
Sema4 Holdings — J.P. Morgan Healthcare Conference 2022 on 6ix